EGFR and central nervous system cancer: An EGFR-directed ADC, depatuxizumab mafodotin (Depatux-M, formerly ABT-414), which uses the mAb806 antibody against a tumor-specific EGFR epitope, demonstrated potent anti-tumor effects in preclinical glioma models with EGFR overexpression, EGFR amplification, or EGFRvIII mutations (Van Den Bent et al., 2020; von Achenbach et al., 2024; Lassman et al., 2023).